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Background: Deep Brain Stimulation (DBS) is an underutilized surgical therapy for
Parkinson’s Disease (PD). Both physician and patient hesitancies have been described
as potential barriers to DBS, but the specifics of patient perceptions of DBS have not
been well-characterized in the general PD population.
Objective: To characterize the understanding and impressions of surgical therapy in PD
patients prior to formal surgical evaluation.
Methods: A 30-question survey assessing impressions of surgical therapy for PD
and understanding of DBS for PD was administered to PD patients seen at an urban
movement disorders clinic.
Results: One hundred and two patients completed the survey. When asked if they
would undergo a hypothetical risk-free, curative brain surgery for PD, 98 patients
responded “yes.” Patients were more agreeable to “reversible,” “minimally-invasive,” and
“incisionless” surgery. 51.2% thought DBS is an “effective” treatment for PD, 76.6%
thought it was “invasive,” and 18.3% thought it was “reversible.” 45.2% reported fear of
being awake during DBS surgery. Regarding costs, 52.4%were concerned that DBSwas
“very expensive” or “not covered by insurance.” Initial source of information and perceived
treatment effectiveness were not associated with concerns about DBS effectiveness or
threats to normality. Negative perceptions of past surgery were associated with concerns
about DBS altering mood and personality.
Conclusion: Overall, patients expressed concerns regarding procedural efficacy,
invasiveness, cost, and irreversibility—independent of the original source of information.
Future studies are required to allow us to better understand the impact of these initial
findings on DBS hesitancy and underutilization.
Keywords: DBS, Parkinson’s disease, patient perspectives, patient education, patient-doctor relationship
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INTRODUCTION
Deep Brain Stimulation (DBS) is an effective surgical therapy
for PD, showing benefit for motor complications as well as
improvement in quality of life (1–6). It is a cost-effective
treatment (7) with clear long-term benefit and high patient
satisfaction (8–10). Despite the existing evidence, DBS therapy
for PD may be underutilized (11), with current literature noting
that as few as 10–15% of eligible PD patients are referred to DBS
treatment centers (12). Physician hesitancy has been identified
as a potential factor for DBS underutilization (12). Patient-
specific barriers have also been identified; and it is estimated that
approximately half of advanced PD patients undergoing surgery
express reluctance prior to implantation (13). Given the salient
role of patient impressions and understanding in choosing to
undergo certain neurosurgical procedures (14, 15), it is possible
that similar trends could be influencing DBS utilization.
Patients are often the drivers of the decision to undergo
DBS, with about half of patients taking their own initiative
when considering treatment (16). Despite the significant role
of patient perspective, few studies have examined how patients
conceptualize DBS prior to considering surgery (17). To date,
no studies have examined impressions of DBS invasiveness or
effectiveness in the general PD population, prior to discussing
implantation with surgical providers. Since the few existing
studies on patient perceptions of DBS have been restricted to
those who ultimately undergo surgical evaluation, their findings
may not be representative of the larger PD population.
As such, we aimed to characterize the understanding and
impressions of surgical therapy in a general population of
PD patients prior to formal surgical evaluation. We therefore
developed this pilot investigation to provide a foundational
understanding of how patients at an urban, tertiary movement
disorders clinic learn about and perceive DBS therapy.
METHODS
This study was approved by the local Institutional Review Board.
Informed consent was obtained following patient recruitment
prior to survey administration. Data was collected and relevant
personal identifiers were removed before analysis in order to
protect patient privacy. We confirm that we have read the
Journal’s position on issues involved in ethical publication and
affirm that this work is consistent with those guidelines.
Survey Design
A survey was created in order to capture impressions of
hypothetical surgical treatment of PD and of DBS therapy.
The survey consisted of 30 questions (Supplementary Figure 1),
designed by two medical students (SD and MB), a Movement
Disorders Neurologist (TW), and a Functional Neurosurgeon
(CW). Questions were developed based on prior studies (14,
17) and common patient impressions previously noticed by the
clinicians. The survey also contained additional questions about
past surgical history in order to account for possible missing data
in the medical records.
The questions were intentionally designed to allow
participants to interpret specific terms that are commonly
used to describe surgical procedures. The phrasing of questions
was therefore matched across series of questions while changing
the term of interest. Patients were not allowed to discuss their
interpretation of the questions with their provider or study
administrators. The survey did not have “I do not know” or
free-text options, and thus participant responses were limited by
the their sole interpretation of each survey question.
Patient Selection
Consecutive patients with a diagnosis of PD were selected to
participate in the survey by a movement disorder neurologist
(TL, DK, and JR) after a routine scheduled evaluation.
Selection criteria included patients who had not undergone
DBS implantation or referral to a neurosurgeon for consultation
regarding DBS surgery. All DBS-naïve patients were eligible,
and quality of their DBS candidacy was not considered. Having
had prior discussions of DBS with a neurologist or other
healthcare provider were not cause for exclusion. Patients with
cognitive impairment that would preclude independent survey
participation (e.g., dependence on a care-giver to respond to
survey), as judged by their neurologist, were excluded from
the study.
Survey Administration
A research assistant was present to administer and collect the
survey. Patients were required to complete the questionnaire
based on their own interpretation of the questions and with
the assistant available to answer questions but provide minimal
direction in order to reduce bias. Following completion of
the survey, the researcher interviewed patients to complete the
Schwab & England Activities of Daily Living Scale (SE).
Demographic and Clinical Data
Demographic variables including age and sex were collected.
Clinical data collected from chart review included the MDS-
UPDRS III score at the time of the visit, Levodopa Equivalent
Daily Dose (LEDD) at time of visit, and years since diagnosis.
Statistical Analysis
Statistical analyses were performed using RStudio 1.2.1335
(RStudio, Inc., Boston, MA). The distribution of continuous
variables was tested using direct visualization of histograms and
the Shapiro-Wilks test. Spearman’s rho was used to evaluate the
correlation between the demographic variables estimating the
severity of disease and the willingness to undergo DBS. The
source of DBS information was evaluated as a potential influence
factor for impressions of DBS. The Mann-Whitney test was used
for a binary analysis (source of information= physician vs. other
sources). Likewise, the Kruskal-Wallis test, along with the Dunn’s
post-hoc test, was used to test if experience with previous surgeries
could influence the perceptions of DBS. Any variable with a
p-value < 0.05 was considered to be statistically significant.
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RESULTS
Demographics
A total of 104 patients completed the survey between
November 2018 and February 2020 (Table 1). Two patients
were excluded due to one requiring a caregiver to fill out
the survey and another having had the DBS procedure prior
to enrollment.
TABLE 1 | Patient demographics.
Demographics
N 102
Age 67.66 ± 9.13
Sex 39.2% F
Years since diagnosis 6.02 ± 3.61 (1–16)
Average UPDRS score 18.27 ±.67 (1–45)
Average LEDD score 601.73 ± 9.67 (0–2,910)
Average Schwab and England score 83.35 ± 17.20 (10–100)
Previous surgery 88 Yes (86.3%)
Impression of prior surgery 70.5% Positive
Familiar with DBS 82 Yes (80.4%)
UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, Levodopa Equivalent Daily
Dose; DBS, Deep Brain Stimulation.
Regarding PD and Hypothetical Surgeries
Most patients who reported a prior surgical history (including
non-brain related surgeries) were satisfied (70.5%) with their
previous procedure (Table 1). When asked if they would undergo
a hypothetical, risk-free, curative brain surgery for their PD,
98 patients (96.1%) responded “yes.” Assuming that surgery
would be the best treatment option available, most patients
(>69.6%) would consider either reversible,minimally-invasive, or
incisionless surgery (Figure 1). Severity of disease (as estimated
by the UPDRS III, LEDD, and SE) was not correlated with the
willingness to undergo DBS (Spearman’s rho = 0.07, −0.05,
−0.01, and p= 0.51, p= 0.68, p= 0.97, respectively).
Most patients agreed that PD progresses and worsens over
time (83.4%), but were also satisfied with their current treatment
(75.5%). Over twice as many patients reported that they would
participate in PD clinical trials for drug therapies (72.5%)
compared to surgical therapies (30.4%) (Figure 1).
Impressions of DBS
Eighty-two (80.3%) patients reported familiarity with DBS, with
the majority having first heard about it from the internet or a
physician (Figure 2).
Approximately half (51.2%) of our cohort agreed that DBS
is effective for PD. Most patients thought that DBS is invasive
(76.6%) and only as a last resort (62.1%). A plurality of patients
(46.3%) believe that DBS is not reversible. Smaller portions of
our cohort expressed concerns about DBS altering appearance
FIGURE 1 | Patient responses (n = 102) to questions regarding impressions of hypothetical brain surgeries (top); and to questions regarding efficacy of their
treatment, Parkinson’s Disease progression, and openness to novel therapies (bottom). Percentages for each response category are shown: “Agree” (responses of 4
or 5, in green), “Neutral” (response of 3, in yellow), and “Disagree” (responses of 1 or 2, in red).
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FIGURE 2 | Distribution of initial sources of information (left); and patient responses to questions regarding DBS impressions (right) among our DBS-aware cohort
(n = 82). Percentages for each response category are shown: “Agree” (responses of 4 or 5, in green), “Neutral” (response of 3, in yellow), and “Disagree” (responses
of 1 or 2, in red).
FIGURE 3 | Distribution of the earliest time interval in which DBS-aware patients would consider DBS (n = 82).
(20.8%), personality (30.5%), mood and well-being (34.2%), or
negative impacts on activities of daily living (32.9%). Almost half
of our cohort (45.2%) expressed fears about being awake during
the DBS procedure. The majority of patients (76.8%) expressed
concerns or were neutral when reporting impressions of DBS
insurance coverage. Over half (52.4%) of our cohort reported
concerns about either expense or insurance coverage (Figure 2).
Patients held various opinions about the time period
after which they would consider undergoing DBS should
their symptoms worsen. A single patient said they would
never consider DBS; 11% of patients would consider DBS
in 10 or more years, and 26% of patients would consider
DBS in 1 year or less. The remaining percentage of our
cohort was split almost evenly amongst patients agreeing to
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DBS in 1–3 years (22%), 3–5 years (17%), and 5–10 years
(26%) (Figure 3).
Factors Influencing Impressions of DBS
We analyzed if the source of DBS information could affect
the impressions on DBS. Patients reported myriad sources with
regards to where they became familiar with DBS (Figure 2). A
physician being the source of information did not influence the
perceptions of DBS (Table 2). In addition, we also evaluated
if their experience of previous surgeries could affect the
impressions on DBS. In those who identified prior surgery as a
negative experience, we found a higher degree of concerns about
DBS altering mood and emotional well-being (p-value = 0.02,
post-hoc Dunn test: p = 0.05). There were no similar findings
when subjects were asked about concerns regarding DBS being
effective, invasive, reversible, expensive, covered by insurance, new
and unproven, a last resort procedure, and altering personality,
appearance, or activities of daily living (Table 3).
DISCUSSION
In this study, we surveyed 102 patients with PDwho had not been
formally evaluated for DBS to obtain an initial understanding
about their attitude toward PD surgery and their understanding
of DBS. The results of our study help to further capture
patient attitudes toward surgery and DBS for treatment of their
PD. Furthermore, our study’s results begin to capture how
patients may view commonly used descriptions of DBS, such
as the procedure being “reversible” or “non-invasive.” Most
notably, only approximately half of our DBS-aware patients
thought that it is an effective treatment for PD. In addition,
cost or insurance coverage was a concern for the majority of
patients. Such impressions and concerns regarding DBS may
contribute to patients’ reluctance to even initiate discussions with
a neurosurgeon—as fewer than 30% of eligible patients may agree
to further evaluation at specialized DBS treatment centers (18).
DBS Knowledge and Initial Sources of
Information
Consistent with prior studies, our data demonstrates that most
patients first learn about DBS either from the internet or from a
physician (17, 19, 20). While it has been suggested that internet-
based patient testimonials may inflate patient expectations of
DBS (21), we found no correlation between patient impressions
of DBS and the initial source of their information. At the same
time, our survey did not allow subjects to specify the details
of the internet sources. Little is known about communication
regarding DBS in online forums; however, the role of interactions
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between previously implanted patients and those considering
surgery may be an important factor in patient impressions (19).
A 1-year ethnographic study of DBS internet forums revealed
how implanted patients served as sources of help for patients
considering the procedure (22) and that few healthcare providers
participated in these forums.
In our cohort, learning about DBS from a physician was
not correlated with differences in the impressions of multiple
aspects of DBS surgery, suggesting that even patients who are
informed about DBS by a physician may still believe it to be
ineffective. This finding is particularly noteworthy as it suggests
that despite physicians’ efforts, patients remain uninformed
about DBS efficacy. This discrepancy may suggest that patients
may consider information from healthcare providers and outside
sources to be equally valid, even if the latter may be inaccurate.
Alternatively, patients may ultimately rely on multiple resources
with conflicting information in the process of researching DBS.
The effectiveness of physician communication may also be
variable. It has also been reported that 2 h after participating in
informed consent for a neurosurgical procedure, patients retain
<20% of the information (23). Therefore, patients may refer
to online resources and patient testimonials to fill in gaps of
understanding. With the use of multiple resources, the initial
source of information may not be particularly relevant to shaping
the entire impression patients have of DBS surgery.
Impressions of DBS Efficacy
Approximately half of our DBS-aware cohort agreed that it is an
effective treatment for PD; yet almost 40% of patients reported
that they were uncertain about DBS efficacy. This represents
a disconnect between the impression of DBS efficacy and the
existing evidence for DBS (1–10). This finding is especially salient
given the patient-driven nature of the decision to undergo DBS
reported in previous studies (16, 24). While the reasons for this
misinformation among patients is not clearly evident in our
data, we believe that it raises sufficient concern to justify further
investigation of the population characterized as ambivalent or
uncertain about DBS.
It is possible that PD patients may not be fully aware of the
full range of benefits that DBS therapy can provide; and instead
believe that DBS is helpful only for a single symptom such as
tremor (25). Another possible explanation for the uncertainty
around DBS efficacy is that patient goals of surgical therapy
may not align with what DBS can reasonably offer. Up to 25%
of patients may still express dissatisfaction with DBS despite
improvement of motor control (26), as patients tend to desire
treatments that improve non-motor symptoms as well (27).
Research has found that non-motor symptoms, which are not
directly improved by DBS, are negatively associated with patient
quality of life (28). Thus, the inability of DBS to address these
symptoms may contribute to a patient ambiguity or ambivalence
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about the effectiveness of DBS. This preference may explain why
some patients do not consider DBS to be “effective,” as their
expectations may extend beyond the control of motor symptoms.
Furthermore, patient goals may shift after DBS implantation—
particularly when it comes to the importance of improvements
in non-motor symptoms and behavioral goals (29).
Timing of DBS Surgery
In the DBS-aware cohort, 55% of patients reported that they
would wait at least 3 years before considering DBS; and over
60% of our DBS-aware cohort considered the treatment as
a last resort therapy reserved only for advanced PD. This
sentiment is consistent with prior studies (17, 19), with one
in particular noting that patients qualifying for EARLYSTIM
did not necessarily view themselves as ill enough to undergo
DBS. Yet, the results of the EARLYSTIM study have suggested
that DBS may be considered once motor complications lead
to significant disability despite optimal medical management
(30, 31). Interestingly, the correlation between medication
failure and consideration of DBS was not clearly apparent
in our cohort, as perceived efficacy of their current medical
treatment was not associated with patients’ willingness to
undergo DBS. The persistent view of DBS as a last-resort therapy
is particularly notable given recent findings suggesting that
DBS performed within 4 years of diagnosis may modify disease
progression (32–34).
The Decision Burden: Balancing
Implantation Benefits With Concerns
About DBS Invasiveness, Reversibility, and
Impacts on Normality
A stigma of “brain surgery” certainly exists. This stigma has
been suggested in a study of epilepsy patients, in whom
approximately half of patients were unwilling to undergo a
hypothetical surgery even if it was deemed curative and without
risk (14). We did not identify this same degree of hesitancy
toward hypothetical, risk-free curative PD surgery in our cohort,
suggesting that the stigma suggested in the epilepsy cohort does
not generalize to Parkinson’s patients. The fear of being awake for
DBS surgery may represent a deterrent patients from pursuing
surgical evaluation. Almost half of our cohort expressed this
fear. Discussing the option of DBS implantation under general
anesthesia, which has been shown to be as efficacious as its awake
counterpart (35–40), may reduce this apprehension and thus help
reduce the aforementioned under-utilization of DBS.
As must be done with all surgical interventions, DBS
candidates must weigh the finite therapeutic benefits of DBS
against the risk of complications. Fear of complications is often
the primary contributing factor toward reluctance (13). Our
observation that over twice as many patients in our cohort would
agree to participate in medical trials of novel drugs to treat PD vs.
novel surgeries may reflect increased concern regarding adverse
events from brain surgery (14). That being said, it remains
unclear if the risks associated with DBS surgery are significantly
greater than with medical management. On the one hand, the
rate of levodopa-associated dyskinesia is estimated to be 30–40%
within 5 years according to recent literature (41). On the other
hand, surgical complication rates of DBS for PD are estimated
to be between 1 and 5% (42) and estimates of adverse effects
possibly attributable to DBS stimulation (e.g., impaired speech or
gait, depression, cognitive disturbances) have been estimated to
be ∼23% (43). Patients are tasked with imagining a life of living
with device-based treatment and continuous neurostimulation.
The experience of adapting to a possible new baseline of cognitive
and motor functioning related to stimulation is a reality unique
to DBS (44). While patients generally believe that the therapeutic
benefits outweigh these impacts (9), this unique dimension of
the decision burden may serve as a further barrier to patients
considering DBS therapy. In our cohort, we also found an
correlation between negative experiences with prior surgeries
and a greater concern for alterations in mood and emotional
well-being with DBS.
While surgery described “minimally invasive” or “reversible”
was a factor in our cohort’s consideration of an intervention,
DBS may not resonate as either because it is a permanently
implanted device. Almost twice as many PD patients would
agree to a reversible PD surgery vs. irreversible PD surgery, but
only 18.3% of our DBS-aware cohort agreed that the procedure
was “reversible.” There are mixed perceptions about what is
meant by a hypothetical return to pre-implantation baseline
should patients undergo electrode removal (45). Because we
did not specify in the survey what we meant by “reversible;”
patients may have interpreted this question either as implantation
reversibility or stimulation reversibility. From an implantation
perspective, DBS causes distinct inflammatory changes and
eventual glial scar formation (46, 47); however, longitudinal
studies in animal models have demonstrated that these changes
are largely confined to where electrodes were implanted
(48). With regards to stimulation, plasticity induced by DBS
stimulation may lead to retained clinical benefit (49). Given
the possibility that stimulation induces permanent changes in
neuronal structure or function, viewing DBS as truly reversible
may be a mischaracterization even if a system can be turned
off or removed. While patient knowledge of specific effects
of stimulation may vary, it is possible given our data that
many patients think that continuous neural stimulation is
never truly reversible, even if it can theoretically be turned
off. At the same time, in contrast to ablative procedures,
such as radiofrequency or focused ultrasound lesioning, DBS is
inherently more reversible because a permanent lesion is not
created in the brain.
Costs and Level of Disability as
Determinants of Impressions of DBS
Over half of our DBS-aware cohort reported concerns about
either insurance coverage or cost. Currently, DBS is covered
by most insurance carriers including Medicare; however, factors
such as race, sex, and neighborhood socio-economic status
have been found to predict disparities in treatment among the
insured (50). Studies have found implantation for both early
and advanced PD to be cost-effective (with an estimated 1.7
QALYs added over best medical therapy) despite the upfront and
maintenance costs (7, 51). Implanted individuals may also see
reductions in the costs related to their medications (52). As such,
when discussing costs, providers may benefit from discussing
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DBS implantation as a cost-effective treatment to improve quality
of life. Further studies would be required to understand the
true impact of this gap in understanding on the consideration
of DBS.
Limitations
The multiple-choice format of our questions allowed us to
survey a high-volume of patients; but restricts the diversity
of participant responses. The multiple-choice format did not
include an “I do not know” option, and thus, we recognize
that some patients may have answered “neutral” to indicate
this response. In addition, we note that patients interpreted
our questions subjectively, and the lack of free-response options
constrains the patients’ interpretations. It is important to note
that this study was designed to allow for patient interpretation
in order to better understand how terms commonly used
to describe surgical procedures would affect their opinion of
the intervention. Future areas of investigation can focus on
asking patients about shared common experiences with DBS
perceptions and allow for open responses to help provide
further clarification.
While our results represent patients at US, urban, movement
disorders clinics, from an urban American tertiary care clinic, we
recognize that these findings may not be generalizable to other
settings (e.g., international, rural areas). In addition, only a small
minority of patients had not heard about DBS, and thus their
perspectives may not be as well-represented in our study.
Cognitive impairment was an exclusion criteria; however, a
complete mental status evaluation with scores (i.e., mini mental
state examination) was not performed for each subject. Based on
the neurologist assessment during the visit, patients who were
dependent on a care-giver to respond to survey or with severe
dementia were not offered to participate in the study. Therefore,
there is a potential bias of patients with borderline cognitive
decline who were not identified during clinical assessment.
Finally, we note that the patients recruited in our study are
widely varied in disease duration, clinical staging, and therapeutic
regimen. These factors all have the potential to impact a patient’s
quality of life and thus their willingness to accept DBS. While
we attempted to elucidate how these factors may affect patient
impressions via our analysis, we note that studies with more
homogenous cohorts are necessary to connect impressions of
DBS to clinical scales of PD.
CONCLUSIONS
The decision to implant a device to modulate the brain is a
complex, multifactorial decision that is ultimately driven by
the individual and the information obtained from a variety
of sources including physicians, the internet, other patients,
family, friends, and patient support groups. Providers should
have frank discussions with patients about their knowledge of
DBS in order to assess their impressions and understanding of its
effectiveness for PD symptoms as well as their goals for surgical
therapy. Our data demonstrate that patients voiced greater
overall concerns regarding procedural efficacy, invasiveness,
cost, and lack of reversibility than concerns about threats to
personality, mood and well-being, impacts on activities of daily
living, and changes to appearance. Addressing barriers and
correcting misperceptions about cost may help facilitate open
discussions undergoing DBS.
While this study highlights certain impressions and gaps in
understanding, future studies will be required to establish true
causality and to allow us to better understand the impact of these
initial findings on DBS hesitancy and underutilization.
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